An ethics framework for consolidating and prioritizing COVID-19 clinical trials. (April 2021)

• Record Type: Journal Article
• Authors: Meyer, Michelle N; Gelinas, Luke; Bierer, Barbara E; Hull, Sara Chandros; Joffe, Steven; Magnus, David; Mohapatra, Seema; Sharp, Richard R; Spector-Bagdady, Kayte; Sugarman, Jeremy; Wilfond, Benjamin S; Lynch, Holly Fernandez
• Is Part Of: Clinical trials. Volume 18:Number 2(2021)
• Page Start: 226
• Page End: 233
• Publication Date: 2021-04
• Subjects: COVID-19 -- coronavirus -- research ethics -- clinical trials -- prioritization -- triage; 615.5072405
• DOI: 10.1177/1740774520988669
• Languages: English
• ISSNs: 1740-7745

Abstract

Given the dearth of established safe and effective interventions to respond to COVID-19, there is an urgent ethical imperative to conduct meaningful clinical research. The good news is that interventions to be tested are not in short supply. Unfortunately, the human and material resources needed to conduct these trials are finite. It is essential that trials be robust and meet enrollment targets and that lower-quality studies not be permitted to displace higher-quality studies, delaying answers to critical questions. Yet, with few exceptions, existing research review bodies and processes are not designed to ensure these conditions are satisfied. To meet this challenge, we offer guidance for research institutions about how to ethically consolidate and prioritize COVID-19 clinical trials, while recognizing that consolidation and prioritization should also take place upstream (among manufacturers and funders) and at a higher level (e.g. nationally). In our proposed three-stage process, trials must first meet threshold criteria. Those that do are evaluated in a second stage to determine whether the institution has sufficient capacity to support all proposed trials. If it does not, the third stage entails evaluating studies against two additional sets of comparative prioritization criteria: those specific to the study and those that aim to advance diversification of an institution's research portfolio. To implement these criteria fairly, we propose that research institutions form COVID-19 research prioritization committees. We briefly discuss some important attributes of these committees, drawing on the authors' experiences at our respective institutions. Although we focus on clinical trials of COVID-19 therapeutics, our guidance should prove useful for other kinds of COVID-19 research, as well as non-pandemic research, which can raise similar challenges due to the scarcity of research resources.